MAPK3 and neuroblastoma: ERK1/2 inhibitor FR180204 combined with imatinib showed more synergistic action on NB cell death than JAK2 inhibitor AG490 and significantly inhibited NB cells’ long-term proliferation in the presence of imatinib (Fig. S12b).